Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia

Stopped early · Phase 1

Conditions studied: Oral Leukoplakia

In brief

This phase I trial studies the side effects and best dose of photodynamic therapy using aminolevulinic acid in treating patients with oral leukoplakia. Photodynamic therapy uses a drug, such as aminolevulinic acid, that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using aminolevulinic acid may be effective against oral leukoplakia.

Key facts

Study ID

NCT00571558

Run by

National Cancer Institute (NCI)

People needed

15

Starts

2008-03-01

Expected to finish

2010-11-01

Last updated by the study team

2014-10-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Northwestern University — Chicago, Illinois, United States
• Robert H. Lurie Comprehensive Cancer Center — Chicago, Illinois, United States
• University of Chicago — Chicago, Illinois, United States
• Froedtert and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.